Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: Lessons learned from a clinical trial comparing biphasic and basal analogues

Health and Quality of Life Outcomes

Volumn 5, Issue , 2007, Pages

  Brod, Meryl ^a   Cobden, David ^b   Lammert, Morten ^c   Bushnell, Donald ^d   Raskin, Philip ^e  

^a Brod Group   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

^d Health Research Associates Inc   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIPHASIC INSULIN; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOGLYCEMIA; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PREDICTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; INSULIN ASPART; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PATIENT SATISFACTION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33847634381     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-5-8     Document Type: Article

References (42)

1. Weaver M Patrick DL Markson LE Martin D Frederic I Berger M Issues in the measurement of satisfaction with treatment Am J Man Care 1997 3 579-594
2. Albrecht G Hoogstraten J Satisfaction as determination of compliance Community Dent Oral Epidemiol 1998 26 139-146 10.1111/ j.1600-0528.1998.tb01940.x 9645408
3. Atkinson MJ Kumar R Cappelleri JC Hass SL Hierarchical construct validity of the treatment Satisfaction Questionnaire for Medication (TSQM Version ll) among outpatient pharmacy consumers Value Health 2005 8 S9-S24 10.1111/j.1524-4733.2005.00066.x 16336491
4. Menzin J Langley-Hawthorne C Friedman M Boulanger L Cavanaugh R Potential short-term economic benefits of improved glycemic control: A managed care perspective Diabetes Care 2001 24 51-55 11194241
5. Hogan P Dall T Nikolov P American Diabetes Association Economic Costs of Diabetes in the U.S. in 2002 Diabetes Care 2003 26 917-932 12610059
6. Anderson RT Marrero D Skovlund SE Cramer J Schwartz S Self-reported compliance with insulin injection therapy in subjects with type 1 and 2 diabetes Diabetologia 2003 46 A275 10.1007/s00125-003-1112-x
7. Rosenstock J Cappelleri JC Bolinder B Gerber RA Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes Diabetes Care 2004 27 1318-1323 15161782
8. Clark CM Jr Snyder JW Meek RL Stutz LM Parkin CG A systematic approach to risk stratification and intervention within a managed care environment improves diabetes outcomes and patient satisfaction Diabetes Care 2001 24 1079-1086 11375374
9. Colman SS Brod MI Krishnamurthy A Rowland CR Jirgens KJ Gomez-Mancilla B Treatment satisfaction, functional status and health related quality of life of patients with migraine randomly assigned to almotriptan or aumatriptan Clin Ther 2001 23 127-145 10.1016/S0149-2918(01)80036-9 11219473
10. Weijman I Ros WJ Rutten GE Schaufeli WB Schabracq MJ Winnubst JA Frequency and perceived burden of diabetes self-management activities in employees with insulin-treated diabetes: Relationships with health outcomes Diabetes Res Clin Pract 2005 68 56-64 10.1016/ j.diabres.2004.08.004 15811566
11. Anderson RT Skovlund SE Marrero D Levine DW Meadows K Brod M Balkrishnan R Development and validation of the insulin treatment satisfaction questionnaire Clin Ther 2004 26 565-578 10.1016/S0149-2918(04)90059-8 15189754
12. Testa M Improving diabetes therapy: Improving satisfaction Diabetes Voice 2003 48 23-25
13. Brod M Skovlund SE Wittrup-Jensen KU Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience Qual Life Res 2006 15 481-491 10.1007/ s11136-005-1624-6 16547787
14. Atkinson MJ Sinha A Hass SL Colman SS Kumar RN Brod M Rowland CR Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2004 2 12 398419 14987333 10.1186/1477-7525-2-12
15. Greenfield S Kaplan SH Kahn R Ninomiya J Griffith JL Profiling care provided by different groups of physicians: Effects of patient case-mix (bias) and physician-level clustering on quality assessment results Ann Intern Med 2002 136 111-121 11790062
16. Cappelleri JC Gerber RA Kourides IA Gelfand RA Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes Diabetes Care 2000 23 1799-1803 11128356
17. Redekop WK Koopmanschap MA Stolk RP Rutten GE Wolffenbuttel BH Niessen LW Health-related quality of life and treatment satisfaction in Dutch patients with Type 2 diabetes Diabetes Care 2002 25 458-463 11874930
18. Taylor MD Frier BM Gold AE Deary IJ Edinburgh Prospective Diabetes Study Psychosocial factors and diabetes-related outcomes following diagnosis of type 1 diabetes in adults: The Edinburgh prospective diabetes study Diabet Med 2003 20 135-146 10.1046/j.1464-5491.2003.00887.x 12581265
19. Petterson T Lee P Hollis S Young B Newton P Dornan T Well-being and treatment satisfaction in older people with diabetes Diabetes Care 1998 21 930-935 9614610
20. Bech P Moses R Gomis R The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naive Type 2 diabetes: A placebo-controlled, multicentre study Qual Life Res 2003 12 413-425 10.1023/A:1023495106160 12797714
21. Herman WH Ilag LL Johnson SJ Martin CL Sinding J Al Harthi A Plunkett CD LaPorte FB Burke R Brown MB Halter JB Raskin P A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes Diabetes Care 2005 28 1568-1573 15983302
22. Wilson M Moore MP Lunt H Treatment satisfaction after commencement of insulin in Type 2 diabetes Diabetes Res Clin Pract 2004 66 263-267 10.1016/j.diabres.2004.04.010 15536023
23. Brod M Lammert M Raskin P Comparison of treatment satisfaction of twice-daily BIAsp 70/30 with once-daily insulin glargine in patients with type 2 diabetes Poster presented at the 65th Scientific Session of the American Diabetes Association Meeting - San Diego, California, 2005. of the American Diabetes Association Meeting - San Diego, California 2005
24. Bradley C Plewe G Kliebe-Frisch Treatment satisfaction with a basal insulin added to oral agents versus twice-daily premixed insulin alone in patients with Type 2 diabetes Diabetes 2005 54 A304
25. Raskin P Bode PW Marks JB Hirsch IB Weinstein RL McGill JB Peterson GE Mudaliar SR Reinhardt RR Continuous subcutaneious insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24 week study Diabetes Care 2003 26 2598-2603 12941725
26. Hoogma RP Spijker AJ van Doorn-Scheele M van Doorn TT Michels RP van Doorn RG Levi M Hoekstra JB Quality of Life and metabolic control in patients with diabetes mellitus type 1 treated by continuous subcutaneous insulin infusion of multiple daily insulin injections Neth J Med 2004 62 383-387 15683093
27. Raskin P Allen E Hollander P Lewin A Gabbay RA Hu P Bode B Garber A INITIATE Study Group Initiating insulin therapy in type 2 diabetes Diabetes Care 2005 28 260-265 15677776
28. Korytkowski M Bell D Jacobsen C Suwannasari R FlexPen Study Team A multicenter, randomized open-label comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus Clin Ther 2003 25 2836-2848 10.1016/S0149-2918(03)80337-5 14693308
29. Rubin RR Peyrot M Quality of life, treatment satisfaction and treatment preference associated with use of a pen device delivering a pemixed 70/ 30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies Diabetes Care 2004 27 2495-2497 15451924
30. Summers KH Szeinbach SL Lenox SM Preference for insulin delivery systems among current users and nonusers Clin Ther 2004 26 1498-1505 10.1016/ j.clinthera.2004.09.009 15531012
31. Peyrot M Rubin RR Lauritzen T Skovlund SE Snoek FJ Matthews DR Landgraf R Kleinebreil L The International DAWN Advisory Panel Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study Diabetes Care 2005 28 2673-2679 16249538
32. Garber AJ Wahlen J Wahl T Bressler P Braceras R Allen E Jain R Attainment of glycaemic goals in type 2 diabetes with once-twice, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study) Diabetes Obes Metab 2006 8 58-66 10.1111/j.1463-1326.2005.00563.x 16367883
33. Kann P Wascher T Zackova V Moeller J Medding J Szocs A Mokan M Mrevlje F Regulshki M Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride Exp Clin Endocrinol. Diabetes 2006 114 9 527-32 10.1055/s-2006-949655 17115351
34. Goudswaard AN Stolk RP Zuithoff P de Valk HW Rutten GE Starting insulin in type 2 diabetes: Continue oral hypoglycemic agents? A randomized trial in primary care The J Fam Pract 2004 53 393-399
35. Shaw WS Zaia A Pransky G Winters T Patterson WB Perceptions of provider communication and patient satisfaction for treatment of acute low back pain J Occup Environ Med 2005 47 1036-1043 10.1097/ 01.jom.0000172863.26222.14 16217244
36. Hirsh AT Atchison JW Berger JJ Waxenberg LB Lafayette-Lucey A Bulcourf BB Robinson ME Patient satisfaction with treatment for chronic pain: predictors and relationship to compliance Clin J Pain 2005 21 302-310 10.1097/01.ajp.0000113057.92184.90 15951647
37. McCracken LM Klock PA Mingay DJ Asbury JK Sinclair DM Assessment of satisfaction with treatment for chronic pain J Pain Symptom Manage 1997 14 292-299 10.1016/S0885-3924(97)00225-X 9392923
38. Niskanen L Jensen EJ Rastam J Nygaard-Pedersen L Erichsen K Vora JP Randomized, multinational open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispor 25 and pen devices in adult patients with Type 2 diabetes mellitus Clin Ther 2004 26 531-540 10.1016/S0149-2918(04)90055-0 15189750
39. Asakura T Seino H Assessment of dose selection attributes with audible notification in insulin pen devices Diabetes Technol Ther 2005 7 620-626 10.1089/dia.2005.7.620 16120036
40. Ray JA Valentine J Nicklasson L Cobden D Raskin P Garber A Palmer AJ Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphaic insulin aspart 70/30 vs. insulin glargine in the US Diabetes Obes Metab 2007 9 103-113 10.1111/ j.1463-1326.2006.00581.x 17199725
41. Valentine WJ Palmer AJ Lammert M Nicklasson L Foos V Roze S Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/ 70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Curr Med Res Opin 2005 21 2063-2071 10.1185/030079905X74989 16368057
42. Hurwitz EL Morgenstern Yu F Satisfaction as a predictor of clinical outcomes among chiropractic and medical patients enrolled in the UCLA low back pain study Spine 2005 30 2121-2128 10.1097/ 01.brs.0000180639.67008.d0 16205336